文献速递传染病防控与疫情报告卫生政策与健康促进

比利时2020年全国血清学调查:估算低流行国家乙肝病毒血清阳性率需联合HBsAg与抗-HBc检测

Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020.
PubMed 文献 · Euro Surveill · 2026-01-01

该研究基于2020年比利时全国人群血清学调查的4,955份 leftover 血清样本,分析HBsAg单独或联合抗-HBc阳性作为感染标准的HBV患病率。仅用HBsAg估计的加权血清阳性率为0.74%(95%CI: 0.50-1.04),而联合抗-HBc阳性后HBV患病率为0.25%(95%CI: 0.13-0.42)。研究强调在低流行国家HBsAg阳性样本中抗-HBc确认检测对提高患病率估计准确性至关重要。

要点

  • 仅用HBsAg估计HBV患病率可能高估,联合抗-HBc确认可提高准确性。
  • 比利时2020年调查中HBsAg加权血清阳性率为0.74%,联合抗-HBc阳性后为0.25%。
  • ≤33岁人群HBsAg/抗-HBc患病率低于年长者,与疫苗接种政策一致。

核心结论

  • 在低流行国家,HBsAg阳性样本需进行抗-HBc确认检测以准确估算HBV患病率。

研究设计与样本

  • 全国人群为基础的血清学调查,分析2020年SARS-CoV-2血清流行病学研究剩余的4,955份血清样本,按地区、10岁年龄组和性别分层,对不一致样本进行抗-HBc中和确认试验。

主要发现

  • HBsAg检出率为0.75%(37/4,955),其中62.2%(23/37)抗-HBc阴性且中和试验无特异性抗-HBc信号。
  • 加权分析估计HBsAg血清阳性率为0.74%(95%CI: 0.50-1.04)。
  • 联合HBsAg和抗-HBc双阳性估计的HBV患病率为0.25%(95%CI: 0.13-0.42)。
  • ≤33岁人群HBsAg/抗-HBc患病率低于年长者(0.079% vs 0.36%;p=0.015)。
  • ≤5岁儿童(n=87)中无双重阳性样本。

关键数值与推荐

  • 感染标准:HBsAg单独阳性或HBsAg联合抗-HBc阳性。
  • 对不一致样本进行抗-HBc中和确认试验。

临床怎么用

  • 在低流行地区进行HBV血清学监测时,对HBsAg阳性样本应补充抗-HBc检测以排除假阳性。
  • 联合检测策略可更准确评估HBV真实负担,指导消除政策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDThe World Health Organization aims to eliminate hepatitis B virus (HBV) by 2030 through reducing incidence and mortality. Accurate prevalence estimates are crucial to guide policies and monitor progress towards HBV elimination. However, HBV prevalence can be overestimated when relying solely on hepatitis B surface antigen (HBsAg) because of unconfirmed or false-positive results. Robust screening algorithms to improve diagnostic accuracy and minimise false positives are required.AIMWe conducted a nationwide, population-based serosurvey to estimate HBV prevalence in Belgium by using HBsAg alone or combined with hepatitis B core antibody (anti-HBc) positivity as infection criterion.METHODSWe analysed HBsAg and anti-HBc in a total of 4,955 left-over serum samples from severe acute respiratory syndrome coronavirus 2 sero-epidemiology studies in 2020. Samples were stratified per region, 10-year age band and sex. A confirmatory anti-HBc neutralisation assay was performed in discordant samples.RESULTSWe detected HBsAg in 0.75% (37/4,955) of samples, of which 62.2% (23/37) were anti-HBc-negative and showed no specific anti-HBc signal in the neutralisation assay. None of the samples from ≤ 5-year-olds (n = 87) were double-positive. Weighted analysis estimated HBsAg seroprevalence at 0.74% (95% confidence interval (CI): 0.50-1.04). However, considering double HBsAg and anti-HBc positivity, an HBV prevalence of 0.25% (95% CI: 0.13-0.42) was retained. The HBsAg/anti-HBc prevalence in ≤ 33-year-olds was lower than in older adults (0.079% vs 0.36%; p = 0.015), consistent with Belgium's vaccination policy.CONCLUSIONThis serosurvey reinforces the importance of confirmatory anti-HBc testing in HBsAg-positive samples, particularly in low-endemic countries. Incorporating anti-HBc testing improves the correctness of prevalence estimates.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Furquim d'Almeida A, Ho E, Schüttler C, et al. Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020. Euro Surveill. 2026. PMID: 41684320. doi:10.2807/1560-7917.ES.2026.31.6.2500533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。